Ryan G Aleong1, William H Sauer2, Gordon Davis3, Guinevere A Murphy3, J David Port4, Inder S Anand5, Mona Fiuzat6, Christopher M O'Connor6, William T Abraham7, Stephen B Liggett8, Michael R Bristow9. 1. Section of Cardiac Electrophysiology, University of Colorado Denver, Denver, Colorado. Electronic address: ryan.aleong@ucdenver.edu. 2. Section of Cardiac Electrophysiology, University of Colorado Denver, Denver, Colorado. 3. ARCA Biopharma, Inc., Broomfield, Colorado. 4. ARCA Biopharma, Inc., Broomfield, Colorado; Division of Cardiology, University of Colorado Anschutz Medical Campus, Denver, Colorado. 5. Veterans Affairs Medical Center, University of Minnesota, Minneapolis, Minnesota. 6. Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. 7. Division of Cardiovascular Medicine, Ohio State University, Columbus, Ohio. 8. Center for Personalized Medicine and Genomics, University of South Florida, Morsani College of Medicine, Tampa, Florida. 9. ARCA Biopharma, Inc., Broomfield, Colorado; Division of Cardiology, University of Colorado Anschutz Medical Campus, Denver, Colorado; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Abstract
OBJECTIVES: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF) patients enrolled in the BEST (Beta-Blocker Evaluation of Survival Trial). BACKGROUND: β-blockers have modest efficacy for AF prevention in HFREF patients. Bucindolol's effects on HF and ventricular arrhythmic endpoints are genetically modulated by β₁- and α(2c)-adrenergic receptor (AR) polymorphisms that can be used to subdivide HFREF populations into those with bucindolol effectiveness levels that are enhanced, unchanged, or lost. METHODS:BEST enrolled 2,708 New York Heart Association (NYHA) class III to IV HFREF patients. A substudy in which 1,040 patients' DNA was genotyped for the β₁-AR position 389 Arg/Gly and the α(2c)322-325 wild type (Wt)/deletion (Del) polymorphisms, and new-onset AF was assessed from adverse event case report forms or electrocardiograms at baseline and at 3 and 12 months. RESULTS: In the entire cohort, bucindolol reduced the rate of new-onset AF compared to placebo by 41% (hazard ratio [HR]: 0.59 [95% confidence interval (CI): 0.44 to 0.79], p = 0.0004). In the 493 β₁389 arginine homozygotes (Arg/Arg) in the DNA substudy, bucindolol reduced new-onset AF by 74% (HR: 0.26 [95% CI: 0.12 to 0.57]), with no effect in β₁389 Gly carriers (HR: 1.01 [95% CI: 0.56 to 1.84], interaction test = 0.008). When β₁389 Gly carriers were subdivided by α(2c) Wt homozygotes (n = 413, HR: 0.94 [95% CI: 0.48 to 1.82], p = 0.84) or Del variant carriers (n = 134, HR: 1.33 [95% CI: 0.32 to 5.64], p = 0.70), there was a positive interaction test (p = 0.016) when analyzed with β₁389 Arg homozygotes. CONCLUSIONS:Bucindolol prevented new-onset AF; β₁ and α(2c) polymorphisms predicted therapeutic response; and the 47% of patients who were β₁389 Arg homozygotes had an enhanced effect size of 74%. (Beta-Blocker Evaluation in Survival Trial [BEST]; NCT00000560)
RCT Entities:
OBJECTIVES: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF) patients enrolled in the BEST (Beta-Blocker Evaluation of Survival Trial). BACKGROUND: β-blockers have modest efficacy for AF prevention in HFREF patients. Bucindolol's effects on HF and ventricular arrhythmic endpoints are genetically modulated by β₁- and α(2c)-adrenergic receptor (AR) polymorphisms that can be used to subdivide HFREF populations into those with bucindolol effectiveness levels that are enhanced, unchanged, or lost. METHODS: BEST enrolled 2,708 New York Heart Association (NYHA) class III to IV HFREF patients. A substudy in which 1,040 patients' DNA was genotyped for the β₁-AR position 389 Arg/Gly and the α(2c)322-325 wild type (Wt)/deletion (Del) polymorphisms, and new-onset AF was assessed from adverse event case report forms or electrocardiograms at baseline and at 3 and 12 months. RESULTS: In the entire cohort, bucindolol reduced the rate of new-onset AF compared to placebo by 41% (hazard ratio [HR]: 0.59 [95% confidence interval (CI): 0.44 to 0.79], p = 0.0004). In the 493 β₁389 arginine homozygotes (Arg/Arg) in the DNA substudy, bucindolol reduced new-onset AF by 74% (HR: 0.26 [95% CI: 0.12 to 0.57]), with no effect in β₁389 Gly carriers (HR: 1.01 [95% CI: 0.56 to 1.84], interaction test = 0.008). When β₁389 Gly carriers were subdivided by α(2c) Wt homozygotes (n = 413, HR: 0.94 [95% CI: 0.48 to 1.82], p = 0.84) or Del variant carriers (n = 134, HR: 1.33 [95% CI: 0.32 to 5.64], p = 0.70), there was a positive interaction test (p = 0.016) when analyzed with β₁389 Arg homozygotes. CONCLUSIONS:Bucindolol prevented new-onset AF; β₁ and α(2c) polymorphisms predicted therapeutic response; and the 47% of patients who were β₁389 Arg homozygotes had an enhanced effect size of 74%. (Beta-Blocker Evaluation in Survival Trial [BEST]; NCT00000560)
Authors: Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: Dirk J van Veldhuisen; Halfdan Aass; Dia El Allaf; Peter H J M Dunselman; Lars Gullestad; Matti Halinen; John Kjekshus; Lis Ohlsson; Hans Wedel; John Wikstrand Journal: Eur J Heart Fail Date: 2006-03-29 Impact factor: 15.534
Authors: Stephen B Liggett; Jeanne Mialet-Perez; Surai Thaneemit-Chen; Stewart A Weber; Scott M Greene; Danielle Hodne; Bradley Nelson; Jennifer Morrison; Michael J Domanski; Lynne E Wagoner; William T Abraham; Jeffrey L Anderson; John F Carlquist; Heidi J Krause-Steinrauf; Laura C Lazzeroni; J David Port; Philip W Lavori; Michael R Bristow Journal: Proc Natl Acad Sci U S A Date: 2006-07-14 Impact factor: 11.205
Authors: Hakan Oral; Thomas Crawford; Melissa Frederick; Nitesh Gadeela; Alan Wimmer; Sujoya Dey; Jean F Sarrazin; Michael Kuhne; Nagib Chalfoun; Darryl Wells; Eric Good; Krit Jongnarangsin; Aman Chugh; Frank Bogun; Frank Pelosi; Fred Morady Journal: J Cardiovasc Electrophysiol Date: 2008-02-04
Authors: Jonathan P Piccini; William T Abraham; Christopher Dufton; Ian A Carroll; Jeff S Healey; Dirk J van Veldhuisen; William H Sauer; Inder S Anand; Michel White; Stephen B Wilton; Ryan Aleong; Michiel Rienstra; Steven K Krueger; Felix Ayala-Paredes; Yaariv Khaykin; Bela Merkely; Vladimir Miloradović; Jerzy K Wranicz; Leonard Ilkhanoff; Paul D Ziegler; Gordon Davis; Laura L Emery; Debra Marshall; David P Kao; Michael R Bristow; Stuart J Connolly Journal: JACC Heart Fail Date: 2019-04-29 Impact factor: 12.035
Authors: Mathew R Taylor; Albert Y Sun; Gordon Davis; Mona Fiuzat; Stephen B Liggett; Michael R Bristow Journal: JACC Heart Fail Date: 2014-10-22 Impact factor: 12.035
Authors: David R Van Wagoner; Jonathan P Piccini; Christine M Albert; Mark E Anderson; Emelia J Benjamin; Bianca Brundel; Robert M Califf; Hugh Calkins; Peng-Sheng Chen; Nipavan Chiamvimonvat; Dawood Darbar; Lee L Eckhardt; Patrick T Ellinor; Derek V Exner; Richard I Fogel; Anne M Gillis; Jeff Healey; Stefan H Hohnloser; Hooman Kamel; David A Lathrop; Gregory Y H Lip; Reena Mehra; Sanjiv M Narayan; Jeffrey Olgin; Douglas Packer; Nicholas S Peters; Dan M Roden; Heather M Ross; Robert Sheldon; Xander H T Wehrens Journal: Heart Rhythm Date: 2014-11-18 Impact factor: 6.343
Authors: Kishan S Parikh; Mona Fiuzat; Gordon Davis; Megan Neely; Penny Blain-Nelson; David J Whellan; William T Abraham; Kirkwood F Adams; G Michael Felker; Stephen B Liggett; Christopher M O'Connor; Michael R Bristow Journal: Circ Genom Precis Med Date: 2018-08